Foley is pleased to be a Gold sponsor of the Sino-American Biomedical and Pharmaceutical Association (SABPA) 3rd Annual Pacific Forum. The conference brings together entrepreneurs, scientists, investors, executives, and policy makers to promote life sciences and biotechnology alliances across the Pacific Rim, including the U.S. West coast, greater China region, and Singapore.
Foley Transactional & Securities Practice Partner Adam C. Lenain will lead a panel discussion of business experts on “Practical and Legal Strategies for Successful Trans-Pacific Licensing and Manufacturing Deals.” As the search for novel drug candidates has become more intense among pharmaceutical manufacturers, The People’s Republic of China has emerged as a vital market for US entities. However, expansion into such a developing market carries its own hurdles and risks that must be managed: assets must be protected, business models adapted, and the practicality of cross-cultural deal-making must be considered. This panel of life sciences business and legal leaders will offer first-hand experience related to these and other issues that arise in connection with licensing or manufacturing drug compounds in China to help you navigate a successful business transaction. Foley Private Equity & Venture Capital partner Kenneth D. Polin will also participate in the panel discussion.